4-Iodo-2-nitrotoluene | CAS:41252-97-5

We serve 4-Iodo-2-nitrotoluene CAS:41252-97-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Iodo-2-nitrotoluene

Chemical Name:4-Iodo-2-nitrotoluene
CAS.NO:41252-97-5
Synonyms:4-Iodo-2-nitrotoluene
4-Iodo-1-methyl-2-nitrobenzene
 
Physical and Chemical Properties:
Density 1.9±0.1 g/cm3
Boiling Point 286.9±20.0 °C at 760 mmHg
Melting Point 43 °C
Molecular Formula C7H6INO2
Molecular Weight 263.033
Flash Point 127.3±21.8 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.644
 
Specification:
Appearance:Brown-yellow crystalline powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Iodo-2-nitrotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Iodo-1-methyl-2-nitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Iodo-2-nitrotoluene Use and application,4-Iodo-1-methyl-2-nitrobenzene technical grade,usp/ep/jp grade.


Related News: As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured.6-Chloro-2-hexanone manufacturer The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion.2,9-dibutyldecanedioic acid supplier In addition, a high-standard GMP workshop is under construction and is expected to be put into production within the year. As the capacity bottleneck is broken, the pharmaceutical intermediate business is expected to grow rapidly in the future, providing the company with new growth momentum.2,6-Difluorobenzonitrile vendor The US National Institutes of Health is working on a preventative vaccine, but it will likely take a few months until the first phase of clinical trials get underway, and more than a year until a vaccine might be available, according to experts.Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.